Kruidvat Noodanticonceptie Ulipristal (Ulipristal Acetate)

Ulipristal acetate acts as a selective progesterone receptor modulator. By binding to progesterone receptors in the hypothalamus and ovary, it blocks the luteinising hormone surge that triggers ovulation. This delay or inhibition of ovulation prevents the release of an egg, thereby reducing the chance of fertilisation and subsequent pregnancy.

The exact dose is determined by the prescribing healthcare professional. In most clinical settings a single oral tablet is administered, but the prescriber may adjust the regimen based on individual medical history, timing of intercourse, and other relevant factors. Patients should follow the specific instructions provided by their clinician.

The product is not intended for use during an established pregnancy, and its safety in pregnant women has not been established. Limited data are available regarding use while breastfeeding; therefore, a healthcare provider should be consulted to weigh potential risks and benefits before administration to nursing mothers.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams across international markets. After the request, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including any required cold‑chain handling), and import documentation.

Ulipristal acetate remains effective up to 120 hours after unprotected intercourse, whereas levonorgestrel’s efficacy declines sharply after 72 hours. Ulipristal also works in later phases of the menstrual cycle by more directly inhibiting ovulation, making it a preferred option for later‑presenting users. Both are oral tablets, but ulipristal generally offers higher overall pregnancy‑prevention rates.

Store the tablets at ambient temperature, below 25 °C, in the original packaging to protect them from moisture and direct sunlight. Keep the container tightly closed and out of reach of children. Do not use the product if the packaging is damaged or if the tablets appear discoloured.

The medication is taken orally, usually as a single tablet, with or without water. It should be swallowed whole and not chewed or crushed. For optimal effectiveness, it is recommended to take the tablet as soon as possible after the unprotected event, ideally within the first 24 hours.

Serious adverse reactions, although rare, include severe allergic responses such as anaphylaxis, liver injury indicated by jaundice or dark urine, and persistent vomiting that may lead to dehydration. If any of these symptoms occur, medical attention should be sought immediately. Users should also be alert for signs of severe abdominal pain.

The product should be avoided by individuals with a known hypersensitivity to ulipristal acetate or any of its excipients. It is also contraindicated in women who are already pregnant, and caution is advised for those taking strong CYP3A4‑inducing drugs, as efficacy may be compromised. Consultation with a healthcare professional is essential before use.